Check eligibility
Answer a few health questions and confirm your phone and email. About two minutes.
Tirzepatide is a dual agonist: it acts on the GIP and GLP-1 receptors.
- Filled by a licensed 503A pharmacy
- Clinicians licensed in your state
- Compounded in the USA
Compounded Tirzepatide
GLP-1 prescription therapy for weight loss, reviewed by a licensed provider.
down 22.5%*
Average weight loss in SURMOUNT-1
A 72-week trial of FDA-approved tirzepatide 15 mg.
A trial of the branded medicine, not of compounded tirzepatide, which is not FDA-approved. An average is not a prediction of your result.
HSA / FSA eligible
Every plan includes
- Unlimited care team messaging
- All doses included, one price
- Injection supplies included
- Free shipping
Thoughtful care, step by step
Choose your plan and pay
Pick a plan and pay. Fully refunded if you're not prescribed.
Final Intake & Clinician Review
Add your health history and ID. A licensed clinician in your state decides. A prescription isn't guaranteed.
Delivery
If prescribed, a licensed pharmacy ships it to your door in plain packaging. Compounded medications are not FDA-approved.
Ongoing care
Message your clinician about doses or side effects, and refill from your portal.
How GLP-1 medications workHow GLP-1s work
We would rather you understand the medicine than take our word for it.
It mimics two hormones you already make
After a meal your gut releases incretin hormones, GLP-1 and GIP, that tell the pancreas, the stomach and the brain that food has arrived. Tirzepatide activates both of those receptors and is built to last about a week, so the signal that normally fades in minutes stays on between doses.
Coskun et al., Molecular Metabolism, 2018 — discovery and mechanism of tirzepatide
It slows how fast the stomach empties
Food leaves the stomach more gradually, so a meal keeps you comfortably full for longer instead of spiking and crashing. In a controlled study, tirzepatide delayed gastric emptying much as long-acting GLP-1 medicines do, with the effect strongest in the first weeks and easing as the body adjusts.
It turns down appetite signalling
Acting on appetite centres in the brain, it eases hunger and the constant pull of “food noise”, so smaller portions feel like enough. In a controlled study, people on tirzepatide ate less at a free-choice meal and reported lower appetite than on placebo.
Trial-average weight loss, on a figure like yours.
Pick a figure and slide from week 0 to week 24 of SURMOUNT-1, a trial of FDA-approved tirzepatide. Then set a starting weight to see the trial’s average in pounds, by trial week.
Pick a figure
Enter a starting weight
Average Loss – First 3 Months
Trial average · FDA-approved Tirzepatide
Measured in SURMOUNT-1, a trial of FDA-approved tirzepatide. Compounded tirzepatide was not studied.
0 lbs
byweek 12
A participant who started at 210 lbs weighed, on average, about 195 lbs at week 12, and 163 lbs at week 72 when the trial ended.
SURMOUNT-1 (Jastreboff AM et al., N Engl J Med 2022;387:205–216): 15 mg tirzepatide; mean loss 7.2% at week 12, 22.5% at week 72. A trial average is not a prediction, and compounded versions were not studied.
Illustrations drawn to show the trial’s average on a figure, not patient photos, and not a prediction of your result. The figure beside them is the measured trial average.
Two GLP-1s. One is prescribed for you.
Both are weekly injections of a compounded GLP-1. Your clinician decides which fits your history; here is how they differ.
Compounded Semaglutide
First generation, cost-effective.
down 14.9%*
Average weight loss in STEP-1
68 weeks · FDA-approved semaglutide 2.4 mg
- GLP-1 receptor agonist
- Once weekly, subcutaneous
- Nausea, constipation, diarrhea, fatigue (most often during dose increases)
from $152/moon the 12-month plan
Compounded Tirzepatide
The stronger effect.
down 22.5%*
Average weight loss in SURMOUNT-1
72 weeks · FDA-approved tirzepatide 15 mg
- GIP and GLP-1 receptor agonist
- Once weekly, subcutaneous
- Nausea, diarrhea, vomiting, constipation (most often during dose increases)
from $232/moon the 12-month plan
Trials of the branded medicines, not of compounded semaglutide or tirzepatide, which are not FDA-approved. Averages, not a prediction of your result.
Compounded Tirzepatide questions
What patients ask most before starting. If yours isn't here, your clinician answers it during review.
Compounded Tirzepatide is a once-weekly injection you give yourself at home, under the skin, with a fine, pre-measured needle. Most patients describe it as quick and nearly painless. Your kit arrives with everything you need, and your care team walks you through your first dose.
The most common effects are mild digestive symptoms: nausea, constipation, or reflux, usually early on and easing as your body adjusts. Starting at a low dose and stepping up gradually keeps them manageable for most people. Serious reactions are uncommon; your provider reviews your history before prescribing and stays available if anything comes up.
You're charged at checkout. If a clinician decides treatment isn't right for you, you get a full refund (usually 5–10 business days). Where appropriate, your provider will suggest a safer alternative or a next step.
No insurance is needed. Compounded Tirzepatide is one flat cash price that covers your medication, provider consultations, and shipping, with no membership fee. It's typically HSA/FSA eligible, so you can often pay with pre-tax dollars.
When you’re ready, begin with a short medical intake.
A licensed clinician will review your health and decide whether treatment is appropriate.
